Related Experiment Video
Updated: Jul 10, 2026
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
Epidermal growth factor receptor-targeted therapy for pancreatic cancer
Chris Papageorgio1, Michael C Perry
1Ellis Fischel Cancer Center, University of Missouri-Columbia, Columbia, Missouri 65203, USA.
Abstract:
Clinical and experimental work supports the view that the epidermal growth factor receptor (EGFR) is a relevant target for cancer therapy. Expression of EGFR is exaggerated in pancreatic adenocarcinoma and activation of EGFR appears to have an important role in the growth and differentiation of this and other types of cancers. EGFR-targeted therapeutic approaches have shown clinical activity in advanced human cancers for which chemotherapy over the last 30 years has sustained a mere palliative role at best. Therefore, the need remains for novel anti-cancer therapies that effectively and specifically target epithelial tumor cells while minimizing the toxic side-effects commonly associated with cytotoxic conventional therapies. Agents capable of inhibiting EGFR activity with resultant inhibition of cell proliferation and angiogenesis have significant potential as chemotherapeutic agents for the treatment of pancreatic adenocarcinomas as well as multiple other malignancies.
Insights
Targeting the epidermal growth factor receptor (EGFR) offers a promising strategy for novel cancer therapies. Inhibiting EGFR may effectively treat pancreatic adenocarcinoma and other malignancies by reducing tumor cell proliferation and angiogenesis.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Epidermal growth factor receptor (EGFR) is overexpressed in pancreatic adenocarcinoma.
- EGFR signaling plays a crucial role in the growth and differentiation of various cancers.
- Current chemotherapy offers limited efficacy for advanced cancers, highlighting the need for targeted therapies.
Purpose of the Study:
- To explore the therapeutic potential of targeting EGFR in cancer treatment.
- To investigate agents that inhibit EGFR activity for cancer therapy.
- To identify novel anti-cancer strategies with improved specificity and reduced side effects.
Main Methods:
- Review of clinical and experimental data on EGFR's role in cancer.
- Analysis of EGFR-targeted therapeutic approaches.
- Evaluation of agents inhibiting EGFR, cell proliferation, and angiogenesis.
Main Results:
- EGFR is a validated target in cancer therapy, particularly in pancreatic adenocarcinoma.
- EGFR-targeted therapies have demonstrated clinical activity in advanced human cancers.
- Inhibitors of EGFR show potential for reducing tumor cell proliferation and angiogenesis.
Conclusions:
- Targeting EGFR represents a significant advancement in developing novel cancer therapies.
- EGFR inhibition offers a promising strategy for treating pancreatic adenocarcinomas and other malignancies.
- Developing EGFR-specific agents can lead to more effective cancer treatments with fewer toxicities.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:38Mitogens and the Cell Cycle